SAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) (the “Company” or “Ligand”) and The Rockefeller University (“Rockefeller”) have entered into a Settlement Agreement and Mutual Release (the “Settlement Agreement”). Pursuant to the terms of the Settlement Agreement, the parties have resolved all disputes that have arisen between them in litigation, including Rockefeller’s primary claim relating to the development of PROMACTA® (eltrombopag). In addition, the parties have agreed to jointly seek dismissal with prejudice of all claims and counterclaims asserted in the ongoing litigation between the parties.
